Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Regardless, anywhere in this &10 range is a floor for the stock.
Yup and two weeks from now it will be Bullish. This stock is ridiculous
Great entry point today at 10.64.
This area is a strong floor for this stock.
Commercial stage drug company
With triple digit growth on no Invasive side effects and cash in the bank for next 12 mo this..... Count me in:)
No position currently
You still in this?
Don't fall in love now I'm beginning to hate this bitch
Going back to $30 and beyond $$
Go Go Go
Bet you guys wish you listened to me now $$$$
Everyone vacated here? I see this company going to $50+ in the coming years Jmho
Hmmmm I'm trying to decide if this is a buy right now-
IN at $12 - Looking to breakout - chart screaming buy!
I wouldn't be surprised if nvcr opened $40 plus Monday...real nice news
Novocure's Novel Anti-Cancer Therapy Catches Street Attention FORBES ARTICLE from today
Take a close watchful eye on little known biomedical Novocure (NVCR), whose novel anti-cancer therapy is catching Wall Street’s attention. Its stock has rallied robustly from a low of $15 a share on the day it went public on Oct. 7, 2015, to a high of $30.89 thereafter, before sliding on Nov. 16, to $22. At least one analyst, JMP Securities’ Michael G. King, sees the stock going much higher, rising to at least $43 a share before long.
Novocure went public at an inopportune time – on the day when many investors dumped the biotechnology group because of consumer outrage over the issue of overpriced drugs. As a result, shares of Novocure tumbled some 17% that day. But, no matter. The stock has since rebounded, driven up by the company’s novel product, Optune.
The Food and Drug Administration approved on Oct.5, 2015, Novocure’s lead product, Optune, for the treatment, in combination with temozolomide, of newly diagnosed glioblastoma, the most common type of primary malignant brain tumor. The FDA approval raises the company’s target patient population in the U.S. alone by nearly 70%, according to Novocure analysis.
“Our our sales and marketing team is now actively promoting Optune as a superior therapy for newly diagnosed glioblastoma, as we work to transform the standard of care,” says Asaf Danziger, chief executive officer of Novocure. Optune is the first FDA-approved therapy in more than a decade, he notes, to demonstrate statistically significant extension of survival in newly diagnosed glioblastoma patients.
Novocure points out that some 215 U.S. leading cancer centers have been certified to prescribe Optune as of Sept. 30, 2015, a 10% increase from the prior quarter.
There are nearly 10,000 new cases of primary glioblastoma and their treatment with Optune could help the company generate $1 billion in sales a year within three years, estimates Novocure. Since the company markets the product itself, FDA’s approval alone could mean $700 million-$800 million of profits annually in the U.S., or close to $10 a share, figures some analysts.
With Optune’s approval in the U.S., Europe and Japan, the sales opportunity from glioblastoma alone could be worth more than $2.5 billion, according to JP Morgan analyst Michael G. King. “With no similar therapeutic technologies in existence, or on the horizon, and demonstrated efficacy in combination with the standard of care, we believe tumor treating fields (TTFields), a new treatment modality in oncology, will become part of the new standard of care,” says King, who rates Novocure stock as “outperform.”The FDA approval of Optune “the company faces solid opportunities,” says the analyst.
He believes the company has a “unique business model with its first approved product, representing a hybrid between a device and a therapeutic.”
King, in a recent report to clients, says that the FDA approval of Optune positions the company to penetrate a large market opportunity in glioblastoma. Apart from its effort in seeking approval of Optune, Novocure also has five completed or ongoing phase 2 clinical studies, as well as nine completed pre-clinical studies on various drug candidates.
The FDA approval is being hailed as the most significant advance in brain cancer in more than 10 years and, says King, “should become part of the new reference standard.”
The two-year survival rate among patients treated with Optune in combination with temozolomide was 50% higher than in patients treated with temozolomide alone, according to Novocure’s estimate.
The company continues to work towards expanding its product pipeline. “We remain focused on advancing our clinical pipeline to evaluate the use of Tumor Testing Fields for a variety of additional solid tumors, including ongoing trials in brain metastases, pancreatic cancer, ovarian cancer, and mesotheloma,” says Bill Doyle, Novocure’s executive chairman.
He believes Novocure will “achieve significant growth as we drive adoption of Optune in newly diagnosed glioblastoma and work to transform the standard of care in our first indication.”
Indeed, some big investors believe that with FDA approval of Optune, Novocure has become “the unicorn investment in the treatment of cancer.”
http://www.forbes.com/sites/genemarcial/2015/11/17/novocures-novel-anti-cancer-therapy-catches-street-attention/
Novocure Announces Webcast to Discuss New EF-14 Clinical Trial Analyses and Tumor Treating Fields Presentations from SNO 2015
St. Helier, Jersey – Nov. 17, 2015 – Novocure (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today that it will hold a webcast on Monday, Nov. 23, 2015, beginning at 4:30 p.m. EST to discuss the new EF-14 analyses and Tumor Treating Fields (TTFields) presentations from the 20th Annual Meeting of the Society of Neuro-Oncology.
The new EF-14 clinical trial analyses to be presented at SNO and that will be discussed during the webcast show the use of TTFields therapy with temozolomide did not adversely affect newly diagnosed GBM patients’ quality of life; and, GBM patients who continued TTFields therapy in combination with chemotherapy, including bevacizumab, at first recurrence lived longer than patients who received chemotherapy alone.
Analysts and investors can participate in the conference call by dialing (877)726-5929 for domestic callers and (530)379-4648 for international callers, using the conference ID 81604390. Access the webcast live from the Investor Relations page of Novocure’s website, where it will be available for replay for 14 days following the call.
http://www.novocure.com/news-and-events/news/2015/11-17-2015.aspx
Novocure Announces 18 Presentations on Tumor Treating Fields at SNO 2015 Including New Analyses of the EF-14 Newly Diagnosed Glioblastoma Clinical Trial Data
Quality of life was maintained throughout treatment with Tumor Treating Fields
EF-14 patients who continued Tumor Treating Fields concurrent with second-line chemotherapy at first recurrence of glioblastoma lived significantly longer than patients who received chemotherapy alone
More >>>>>
http://www.novocure.com/news-and-events/news/2015/11-17-2015-a.aspx
Hey Novocure........just a note for you........your stock needs some good news !
Thanks!!
Interesting article that has nothing to do with this company directly;Sort of a history or precursor possibly to what NVCR does and how that previous invention from the 1930s was stopped by the medical community or AMA,etc.Eeerily similar goals and results.I.E.,,,,,,The destruction of tumor cells.
I'm not going to break down the differences in what TTfields do compared to this article and devices within it,just simply posting it.....food for thought I guess;I thought it was an interesting read.
http://www.naturalnews.com/027104_cancer_WHO_Chi.html#
The ATR (average true range) on this stock is running at about 3.00 a day.......expect volatile ...wide swings....feel free to flip part of your shares IF you can time it correctly ...but be aware that a stock never does the same exact thing twice .....
Bwahahahahahaa!!!!!!!
p.s. I've BEEN RATHER subdued lately about posting......I finally came to the conclusion that for the most part it is useless rambling....but could be good for a few discussions instead of incessant pumping or beating on stocks!!!
I do flip and reserve the right to sell any or all of my shares whenever I please,,, so ...don't count on me or rely on me to be here tomorrow or a year from now,,,,,,but I could be.....just depends,,,,,,,,,,,, the stock market,,,, like WABBITS,,,,, is a moving target!! You can't shoot a Wabbit ,until you see one!!!
I simply can't imagine why the stock isn't trading in the mid-30s already!!!
According to this website the "QUIET PERIOD" ends 11/11/15
What exactly will change when this Quiet period ends?
I've seen some news from the company since the IPO but other than their earnings I guess I haven't seen anything material,,,,so maybe after the 11th we could get some unexpected material information?
http://www.nasdaq.com/markets/ipos/company/novocure-ltd-974162-79294
I expect as some others,,,,that the price of this stock could ramp up rapidly as their preclinical trials and clinical trials ramp on the other uses of an already proven product.Couple that with international sales ,saving lives,extending lives.........medicare ,Aetna and other health insurers picking it up will blow the price up I'm fairly certain.
Am I wrong to be thinking this way? Opinions welcome !!
Be Vewwy Vewwy Qwiet ...We're Hunting Wabbits!!!
Shhhhhhhhhhhhhhhhhhhhhhhhhhhhh
I like this stock because even though it is a pharma company it is soooo different and so much more like a tech company mixed with a pharma but I also can appreciate what they are doing and my ever growing confidence in the success of it given FDA approvals and actual sales vs. years of R & D and the "potential" of getting something to the market.They have already arrived with a product that seems to be selling well and only will grow from here.What's not to like?
This is where things get tricky ....LOL! Okay lurkers ..lets get some chatter on here.....
Low of 15 high of 31...beat down to 19 after high of 31 ...on way back up..does it
A.Keep going and find a new high over 31.00?
B. FALTER and fall back
C. Stay around 25.00 until New news can push it higher ?
Thoughts from the lurkers?
I think higher ......I think undervalued in regards to super ground breaking and expanding technology........I think the market has not really caught on to what this technology is doing for cancer patients.
NovoCure reports Q3 EPS ($2.09) vs ($1.45) year ago; revs 104.7% y/y to $8.953 mln (no estimates)http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#nvcr
This stock should increase its market cap by at least 3 to 4 times over the next year. The Optune product has been approved for primary glioblastoma and the company already has built a sales force and trained numerous oncologists in the world's major cancer centers. The approval 10 days ago means these doctors must use it with the chemo or risk being sued. The results from its trials were stunning! The procedure is covered by all private insurers and shortly by cms. The company nets $14,000 per month per patient and the average patient will be on it for 2 yrs. assume that Half the patients get the treatment annually in 3 yrs that means at least 12000 patients will be using it in the us alone $168 million per month or over $ 2 billion just for the U.S. alone double it since it is approved in Europe and Japan. By the way it is also approved for non small cell lung cancer in Europe. With the great results the procedure shows with no side effects it will grow rapidly. They have great patent position, no need to share marketing and as a result Hugh profitability for many years which means a monster p/e multiple. The company is also totally unknown. Next Monday's conference is it coming out party. Stock is going much much higher.
NVCR just hit $28 !!
NVCR 26.45 its getting there !
lets see 30
NVCR 23.23 now !:)
good point ....my guess pretty low until they release the secondary commons.
NVCR
wonder what the float is
agree easy $30
NVCR
NVCR has 30.00 written all over it...if TRIL went to 30 with no rev...and this has FDA approved drugs already and and a very nice cancer hopeful...it could see 40 bucks some day!
agree going to be a good one .g/l .
NVCR
This stock is going to soar IMO no pun intended lol Wish I bought at $14
NVCR $19.88 and climbing .
Followers
|
28
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
559
|
Created
|
10/07/15
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |